Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report published on Friday, MarketBeat.com reports. The brokerage issued an overweight rating and a $5.73 price target on the stock.

A number of other equities research analysts also recently commented on VYGR. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective for the company. Citigroup assumed coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.97.

Voyager Therapeutics Trading Down 4.9 %

Shares of VYGR opened at $5.45 on Friday. The company has a market cap of $297.71 million, a price-to-earnings ratio of 7.68 and a beta of 0.93. The business’s fifty day simple moving average is $6.13 and its two-hundred day simple moving average is $6.84. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period last year, the company earned ($0.59) EPS. As a group, research analysts forecast that Voyager Therapeutics will post -0.89 EPS for the current year.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.53% of the stock is owned by company insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its holdings in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the third quarter worth $74,000. Victory Capital Management Inc. boosted its position in shares of Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares during the last quarter. Hsbc Holdings PLC purchased a new position in Voyager Therapeutics during the second quarter valued at $128,000. Finally, Verition Fund Management LLC bought a new stake in Voyager Therapeutics in the 3rd quarter valued at $216,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.